863,867 Shares in Artivion, Inc. $AORT Purchased by Summit Partners Public Asset Management LLC

Summit Partners Public Asset Management LLC acquired a new position in shares of Artivion, Inc. (NYSE:AORT) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 863,867 shares of the company’s stock, valued at approximately $39,401,000. Summit Partners Public Asset Management LLC owned approximately 1.82% of Artivion at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AORT. Royal Bank of Canada increased its position in Artivion by 107.0% during the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock worth $952,000 after purchasing an additional 20,010 shares in the last quarter. AQR Capital Management LLC grew its holdings in Artivion by 8.8% in the 1st quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after buying an additional 2,823 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Artivion by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after buying an additional 1,032 shares during the period. Creative Planning grew its holdings in Artivion by 5.6% in the 2nd quarter. Creative Planning now owns 14,272 shares of the company’s stock valued at $444,000 after buying an additional 753 shares during the period. Finally, Invesco Ltd. grew its holdings in Artivion by 40.8% in the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after buying an additional 139,370 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Insider Buying and Selling at Artivion

In other news, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the transaction, the senior vice president directly owned 60,259 shares of the company’s stock, valued at $1,247,361.30. The trade was a 42.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is owned by corporate insiders.

Artivion Stock Performance

NYSE AORT opened at $21.41 on Wednesday. The firm has a market capitalization of $1.04 billion, a P/E ratio of 89.23 and a beta of 1.26. Artivion, Inc. has a 1-year low of $19.16 and a 1-year high of $48.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.86 and a quick ratio of 2.80. The business’s 50-day simple moving average is $28.41 and its 200-day simple moving average is $36.62.

Analyst Upgrades and Downgrades

Several research firms have commented on AORT. Needham & Company LLC lowered their price target on Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a report on Friday, May 8th. Citizens Jmp lowered their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Weiss Ratings cut Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 8th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $36.00 price target on shares of Artivion in a report on Tuesday. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $44.17.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.